Comprehensive review for AML treatment. New directions applied in MD Anderson CC Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

New guidelines for treatment of MM (EHA/ESMO) Presenter S. Kastritis Participation Spyridonidis, Liga, Tsokanas Diagnostic obligatory are still Free light chain serum, 24-Urin, cytogenetics (Del17p, t(4,14), WBLD-CT and if  negative Whole body MRI. Asymptomatic MM (use 20/2/20 score), if high (2 of 3) risk score these pats...

https://www.ebmt.org/sites/default/files/2021-02/EBMT%20COVID-19%20guidelines%20v.%2015.02%202021-02-18.pdf Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Ebmt proposes to vaccinate after day 100 https://www.ecdc.europa.eu/en/publications-data/coronavirus-disease-2019-covid-19-and-supply-substances-human-origin Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

An important paper published in Blood showed that prophylaxis is not  always wihtout harm. Pts under letermovir prophylaxis may be at risk for  late CMV infection after HCT because of delay CMV-specific cellular  reconstitution (which is due to the letermovir induced decreased CMV  antigen exposure). JOURNAL ARTICLE Cytomegalovirus-specific T-cell Reconstitution...

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

New England Journal of Medicine. 2020 Dec 24; 383 (26) : 2526-2537. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. Andrew H Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun-Ho Jang, Kimmo Porkka, Dominik Selleslag,...

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

https://register.gotowebinar.com/register/6711366611927088656 Stem Cell Transplantation - a Post ASH 2020 Summary Tuesday, February 2, 2021 Professor Arnon Nagler, MD, MSc Participants: Prof.Spyridonidis, Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Duration of shedding of viable SARS-CoV-2 in severely immunosuppressed  patients with cancer For most patients with COVID-19, persistently positive nucleic acid  testing after symptom resolution does not indicate prolonged  infectiousness. However, accumulating evidence suggests that some  severely immunocompromised patients may have prolonged shedding of  viable SARS-CoV-2. One study of 20 patients with...

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Study showing the different significance of allelia or Niall epic  tp53 mutation in AML as recently showed in MDS Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

We discussed the use of Tki after allo hct for ph + ALL and our current practice. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Kostopoulou Leukemia. 2020 Nov 17; A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT:...

In this large, prospective cohort of fit older adults with advanced MDS, we found that survival was significantly improved if HCT was performed early or for adverse risk disease but not for standard risk disease with severe cytopenia. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas,...